Category: Regulatory DisclosuresBy adminApril 15, 2024 Author: admin https://ramedapharma-ir.com Post navigationPreviousPrevious post:The invitation to shareholders for the AGMNextNext post:Rameda Expands Freely Priced Portfolio with Launch of Ramelact, Egypt’s First Lactase Enzyme Supplement for the treatment of Lactose IntoleranceRelated PostsThe invitation to shareholders for the AGMMarch 31, 2024RetractionMarch 24, 2024Rameda 4Q23 BOD Meeting MinutesMarch 18, 2024BOD Report FY2023- under the Regulatory DisclosuresMarch 18, 2024Annual Corporate Governance Disclosure ReportMarch 18, 2024Rameda 4Q23 BOD Meeting MinutesMarch 18, 2024
